Investigating the RANK/RANKL/OPG pathway might open new scenarios in predicting bone disease recurrence and prognosis and potentially preventing bone metastatization in RANK-expressing early breast cancer patients. This evidence concerns the gene TNFSF11 and breast carcinoma.